☆
Watchlist
Log in
Sign-up
Anteris Technologies Ltd (avr) Logo

Anteris Technologies Ltd (AVR)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

AVR Chart

Snapshot

AVR's Principal Activity is the continued research and development of regenerative medicine.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) +78.62%
vs ASX 200 (1yr) +74.52%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 730 of 2,411
Sector Rank 47 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies MVP / HLA / PGC
EPS -$3.067
DPS $0.00
Book Value Per Share $1.29

Broker Consensus

AVR is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is into continued research and development of regenerative medicine. Products under development in the aortic valve repair and replacement program include DurAVR. Combined with the ADAPT technology this design delivers better haemodynamic performance through unique properties that are critical to longer lasting valves.

Incorporation Details

Incorporated bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011

Corporate Details

Head Office Toowong QLD 4066
Website www.anteristech.com
Registry Computershare
Auditor HLB Mann Judd Chartered Accountants
Date Listed 24 Mar 2004

Upcoming Calendar (Forecasted)

Date Event
19/05/2022 AGM
25/08/2022 Report (Interim)
24/02/2023 Report (Prelim)
25/04/2023 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Stephen (Steve) Denaro Company Secretary,Non-Executive Director Oct 2018

Mr Stephen (Steve) Denaro

Company Secretary,Non-Executive Director

Mr Denaro has more than 30 years of senior level and Board level experience across publicly-listed companies, serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has had manage investment acquisitions and subsequent funding (domestic and international). Mr Denaro has a interest in start-up companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not-for-profit company, National Affordable Housing Consortium Limited. He is Chair of the Risk Management Committee.
Dr Wenyi Gu Non-Executive Director Oct 2018

Dr Wenyi Gu

Non-Executive Director

Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland where he began his postdoctoral work in 2001. Before engaging in nanomedicine, he worked on RNAibased gene therapy for years at Translational Research Institute. Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council to work at Harvard Medical School, Harvard University as a visiting fellow. He is a member of the Risk Management Committee.
Mr Wayne Paterson Managing Director,Chief Executive Officer Feb 2016

Mr Wayne Paterson

Managing Director,Chief Executive Officer

Mr Paterson has held range of senior positions in multinational pharmaceutical companies. Throughout his career, he has been in charge for building and managing businesses throughout the world, including; mergers, integrations, acquisitions and restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, including President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He served as Non-Executive Director of Cepheid Inc from April 2015 to November 2016.
Mr John Seaberg Non-Executive Director,Non-Executive Chairman Oct 2014

Mr John Seaberg

Non-Executive Director,Non-Executive Chairman

Mr Seaberg has experience in cardiovascular products and markets. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chairman of the Board of Synovis Inc. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc. From 1996 to 2006, Mr Seaberg served at Guidant Corp where he served in range of executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical. He is a member of the Risk Management Committee.
Matthew Mcdonnell Chief Financial Officer N/A
David St Denis Chief Operating Officer N/A
Martha Engel General Counsel N/A
Show All

Director Transactions

AVR directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
07/03/22 Stephen (Steve) Denaro Buy +2,222 $18.019 $40,039 On-market trade
03/12/21 John Seaberg Buy +7,000 $8.00 $56,000 Exercise of options
03/12/21 John Seaberg Exercise 7,000 $8.00 $56,000 Exercise of options
07/06/21 Stephen (Steve) Denaro Buy +5,000 $8.009 $40,047 On-market trade
10/12/20 Wayne Paterson Expiry 1,000 $3.80 $3,800 Options expired
10/12/20 John Seaberg Expiry 1,000 $3.80 $3,800 Options expired
20/03/20 Stephen (Steve) Denaro Issued 25,000 $3.50 $87,500 Issue of options
20/03/20 Wayne Paterson Issued 350,000 $3.50 $1,225,000 Issue of options
20/03/20 John Seaberg Issued 60,000 $3.50 $210,000 Issue of options
Show All

Director Interests

The current holdings of AVR directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Stephen (Steve) Denaro 07/03/2022 0 7,222 25,000 N/A
John Seaberg 03/12/2021 15,858 N/A 60,000 N/A
Wayne Paterson 31/12/2020 9,167 N/A 403,248 N/A
Wenyi Gu N/A N/A N/A N/A N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Mar 31, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited A/C 2 650,345 9.90%
National Nominees Limited <Db A/C> 374,479 5.70%
HSBC Custody Nominees (Australia) Limited Gsco Eca 288,924 4.40%
Mercer Street Global Opportunity Fund LLC 280,000 4.26%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 260,807 3.97%
Mr Patrick Chew 176,460 2.69%
Citicorp Nominees Pty Limited 161,115 2.45%
HSBC Custody Nominees (Australia) Limited 150,030 2.28%
CS Fourth Nominees Pty Limited <Hsbc Cust Nom Au Ltd 11 A/C> 129,285 1.97%
Mr Daniel Bernard Clough 89,583 1.36%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 72,987 1.11%
Amedan Pty Ltd 65,340 0.99%
MDM Leby Hwang 59,000 0.90%
Through2 Investments Pty Ltd <Through2 Super Fund A/C> 48,000 0.73%
Sharepoint Solutions Pty Ltd 46,252 0.70%
J P Morgan Nominees Australia Pty Limited 45,476 0.69%
Mr Joseph John Doyle and Mrs Cheryl Anne Doyle 42,326 0.64%
Sean Barrett Pty Ltd <Super Fund A/C> 41,000 0.62%
Mr Donald Fletcher Cameron and Mrs Anne Cameron <Anne & Don Cameron S/F A/C> 40,000 0.61%
BNP Paribas Nominees Pty Ltd CIBC World Markets Inc <Drp> 30,459 0.46%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Perceptive Life Sciences Master Fund Ltd 02/03/2022 1,840,000 14.00
L1 Capital Pty Ltd 07/03/2022 1,137,029 8.39
Sio Partners LP 18/12/2021 1,274,966 12.61

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
02-03-22 Perceptive Life Sciences Master Fund Ltd 1,840,000 -- 14.00
22-02-22 L1 Capital Pty Ltd 538,391 7.16 9.93
05-02-22 Medicus Sciences Acquisition Corp 1,274,966 -- 11.40
18-12-21 Sio Partners LP 12,286 14.38 12.61
01-11-21 L1 Capital Pty Ltd 625,000 -- 7.16
31-05-21 Mercer Street Global Opportunity Fund LLC 383,367 -- 5.52

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
07-03-22 L1 Capital Pty Ltd 26,362 9.93 8.39
15-02-22 Medicus Sciences Acquisition Corp 1,274,966 11.40 --
22-11-21 Sio Partners LP 48,399 19.96 14.38
19-07-21 Mercer Street Global Opportunity Fund LLC 383,367 5.52 --
20-05-21 Mercer Street Global Opportunity Fund LLC 335,383 5.06 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $6.80 30 June
2020 $4.90 30 June
AVR Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.